Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Fluoxetine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Fluoxetine Capsules 40 mg |
| 2 | ACTIVE_COMPARATOR | Prozac Pulvules 40 mg |
| Name | Type | Description |
|---|---|---|
| Fluoxetine Capsules 40 mg | DRUG | 40mg, single dose fasting |
| Prozac Pulvules 40 mg | DRUG | 40mg, single dose fasting |
Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male and/or non-pregnant, non-lactating female. a. Women of childbearing potential must have negative serum beta human chorionic gonadotropin (b-HCG) pregnancy tests performed within 21 days prior to the start of the study and on the evening p...
Fluoxetine is a small molecule drug developed by Viatris Inc. (ticker: VTRS). It is also known as Fluoxetine Capsules 40 mg. The specific therapeutic indication for this formulation is undisclosed, and the drug is in Phase 1 clinical development.
Fluoxetine targets SLC6A4, also known as the serotonin transporter. It acts as an inhibitor of this target. SLC6A4 is a membrane protein that regulates serotonin levels in the brain and other tissues.
Fluoxetine is developed by Viatris Inc., which trades under the ticker symbol VTRS. Viatris is the company responsible for the development of Fluoxetine Capsules 40 mg.
Fluoxetine is in Phase 1 clinical development. It has not been approved by the FDA for any indication. The development program includes one completed Phase 1 trial.
Fluoxetine has been studied in one completed Phase 1 trial, NCT00649636, titled 'Fasting Study of Fluoxetine Capsules 40 mg and Prozac Pulvules 40 mg.' This trial enrolled 32 healthy adult volunteers in the United States and was active-controlled and randomized.